Effect of vitamin D supplementation on serum hepcidin levels in non-diabetic chronic kidney disease patients

被引:1
|
作者
Kamboj, Kajal [1 ]
Yadav, Ashok K. [2 ,6 ]
Kumar, Vivek [1 ]
Jha, Vivekanand [3 ,4 ,5 ]
机构
[1] Postgrad Inst Med Educ & Res, Dept Nephrol, Chandigarh, India
[2] Postgrad Inst Med Educ & Res, Dept Expt Med & Biotechnol, Chandigarh, India
[3] George Inst Global Hlth, UNSW, New Delhi, India
[4] Imperial Coll London, Sch Publ Hlth, London, England
[5] Manipal Acad Higher Educ, Prasanna Sch Publ Hlth, Manipal, Karnataka, India
[6] Postgrad Inst Med Educ & Res, Dept Expt Med & Biotechnol, Chandigarh 160012, India
关键词
Cholecalciferol; chronic kidney disease; hepcidin; IRON-METABOLISM; D DEFICIENCY; INDUCTION; ANEMIA;
D O I
10.4103/ijn.ijn_28_23
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Vitamin D deficiency and anemia frequently coexist. Moreover, vitamin D deficiency is found to play a role in chronic kidney disease (CKD)-associated anemia. We investigated the effect of cholecalciferol on serum hepcidin levels in vitamin D-deficient, non-diabetic individuals with CKD in a randomized, double-blind, placebo-controlled trial.Methods: This study was performed on stored samples of our previously published randomized, double-blind, placebo-controlled trial of cholecalciferol supplementation in non-diabetic patients with stage III-IV CKD and vitamin D deficiency. Stable patients of either sex, aged 18-70 years, with non-diabetic stage III-IV CKD (estimated glomerular filtration rate between 15 and 60 ml/min/1.73 m(2)), and having serum 25-hydroxyvitamin D-3 [25(OH) D] levels <= 20 ng/ml were included. Participants received either two directly observed oral doses of cholecalciferol (300,000 IU) or matching placebo at baseline and at eight weeks. Follow-up was done at 16 weeks. Serum hepcidin levels were analyzed at baseline and at 16 weeks.Results: A total of 120 CKD patients were enrolled. Serum 25(OH) D levels were similar in the placebo and cholecalciferol groups at baseline (13.21 +/- 4.78 ng/ml and 13.40 +/- 4.42 ng/ml; P = 0.88). After 16 weeks, the serum 25(OH) D levels were found to be increased in the cholecalciferol group but not in the placebo group (between-group difference in mean change 23.40 ng/ml; 95% CI: 19.76 to 27.06; P < 0.001). Serum hepcidin levels were similar at baseline (median [IQR]: 33.6 [8.6-77.8] ng/ml vs. 24.6 [9.3-70.7] ng/ml, P = 0.903) and did not vary between groups at 16 weeks (median [IQR]: 41.5 [10.9-75.0] ng/ml vs. 34.8 [12.3-63.75] ng/ml, P = 0.703).Conclusion: Our study provides preliminary data based on which a larger adequately powered clinical trial can be conducted to conclusively assess the impact of vitamin D supplementation on hepcidin levels and anemia in patients with CKD and vitamin D deficiency.
引用
收藏
页码:444 / +
页数:6
相关论文
共 50 条
  • [1] Effect of vitamin D supplementation on serum sclerostin levels in chronic kidney disease
    Yadav, Ashok Kumar
    Kumar, Vivek
    Banerjee, Debasish
    Gupta, Krishan Lal
    Jha, Vivekanand
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2018, 180 : 15 - 18
  • [2] Parathyroid hormone and 25(OH) vitamin D levels in Cameroonian patients with chronic kidney disease: a comparison of diabetic and non-diabetic patients
    Anakeu, A. T.
    Ashuntantang, G.
    Halle, M. P.
    Kaze, F. F.
    Kingue, S.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2014, 103 : S23 - S23
  • [3] Vitamin D levels, vitamin D supplementation, and prognosis in patients with chronic kidney disease
    Namir, Yossef
    Cohen, Matan J.
    Haviv, Yosef S.
    Slotki, Itzchak
    Shavit, Linda
    CLINICAL NEPHROLOGY, 2016, 86 (04) : 165 - 174
  • [4] SERUM VITAMIN D LEVELS IN PATIENTS WITH CHRONIC KIDNEY DISEASE
    Rozita, Mohd
    Afidza, Mohamad Noorul
    Ruslinda, Mustafar
    Cader, Rizna
    Halim, A. Gafor
    Kong, Chiew Tong Norella
    Azmi, Kamaruddin Nor
    Shah, Shamsul Azhar
    EXCLI JOURNAL, 2013, 12 : 511 - 520
  • [5] Correlates of Serum Resistin in Elderly, Non-Diabetic Patients with Chronic Kidney Disease
    Marouga, Anna
    Dalamaga, Maria
    Kastania, Anastasia N.
    Antonakos, George
    Thrasyvoulides, Apollon
    Kontelia, Georgia
    Dimas, Claire
    Vlahakos, Demetrios V.
    CLINICAL LABORATORY, 2013, 59 (9-10) : 1121 - 1128
  • [6] The effect of high-dose vitamin D supplementation on hepcidin-25 and erythropoiesis in patients with chronic kidney disease
    Kristin Danielson Pistis
    Per-Anton Westerberg
    Abdul Rashid Qureshi
    Soheir Beshara
    Gunnar Sterner
    Peter Bárány
    Torbjörn Linde
    BMC Nephrology, 24
  • [7] The effect of high-dose vitamin D supplementation on hepcidin-25 and erythropoiesis in patients with chronic kidney disease
    Pistis, Kristin Danielson
    Westerberg, Per-Anton
    Qureshi, Abdul Rashid
    Beshara, Soheir
    Sterner, Gunnar
    Barany, Peter
    Linde, Torbjorn
    BMC NEPHROLOGY, 2023, 24 (01)
  • [8] Vitamin D Supplementation in Patients with Chronic Kidney Disease
    Cheriet, Sarah
    Royer, Matthieu
    Rajzbaum, Gerald
    Tremollieres, Florence
    JOINT BONE SPINE, 2012, 79 : S110 - S113
  • [9] EFFECT OF EMPAGLIFLOZIN ON SERUM MARKERS OF OSTEOCYTE AND OSTEOBLAST FUNCTION AND ALBUMINURIA IN DIABETIC AND NON-DIABETIC PATIENTS WITH CHRONIC KIDNEY DISEASE
    Masajtis-Zagajewska, Anna
    Paczek, Katarzyna
    Holub, Tomasz
    Nowicki, Michal
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 : 1228 - 1228
  • [10] Effect of probucol on insulin resistance in patients with non-diabetic chronic kidney disease
    Wang, Rui
    Wei, Ri-Bao
    Yang, Yue
    Wang, Na
    Huang, Meng-Jie
    Cao, Cui-Ming
    Wang, Zi-Cheng
    Cai, Guang-Yan
    Chen, Xiang-Mei
    JOURNAL OF GERIATRIC CARDIOLOGY, 2015, 12 (05) : 521 - 527